Senseonics Raises Sales Outlook On U.S. Eversense Growth — But Its Quarterly Loss Widens
Revenue rose approximately 140%, while spending on the commercial organization and new monitors increased.
Senseonics Holdings, which sells implantable glucose monitors for people with diabetes, raised its 2026 sales forecast Monday to $68 million–$70 million from $62 million–$66 million as U.S. Eversense 365 growth outpaced expectations. The earnings release accompanying its SEC filing also showed a wider quarterly loss: $32.7 million, compared with $19.5 million a year earlier.
U.S. Sales Lead The Upgrade
Third-quarter revenue rose approximately 140% to $19.6 million, versus $8.1 million a year earlier. U.S. sales accounted for $16.8 million, up approximately 160% from $6.4 million, with shipment volume reaching a quarterly record and active prescribers increasing approximately 90%.
Outside the U.S., sales reached $2.8 million, approximately 65% higher than the prior year's $1.7 million. Because U.S. growth has exceeded expectations, management now expects international markets to supply approximately 15% of annual revenue.
The revised annual sales range implies growth of 93%–98%. Senseonics also raised its forecast for gross margin—the share of revenue left after product costs—to more than 60%, replacing a 58%–61% range. Its outlook includes consumer marketing, patient assistance programs and the continuing European rollout.
Better Margins, A Bigger Loss
Gross profit reached $12.1 million, compared with $3.5 million a year earlier. Approximately 62% of sales remained after product costs, versus 43%.
Commercial expansion came with substantially higher expenses. Selling and administrative costs reached $32.3 million, versus $15.3 million, which Senseonics attributed to running its U.S. and European commercial organization. Research and development costs were $11.7 million, up from $7.8 million, with management citing Gemini clinical trials and Freedom development.
The quarterly loss per share was $0.50, compared with $0.43. For the first nine months, revenue totaled $45.8 million versus $21.0 million, while net losses reached $101.7 million versus $48.3 million.
At September 30, Senseonics held $126.6 million across cash, restricted cash, cash equivalents and short-term investments. Its Hercules Capital debt had a carrying value of approximately $56.2 million, with $55.0 million of principal outstanding, consistent with the second quarter.
More Inserters And Pump Connections
Senseonics now controls its commercial operations globally, including teams leading European Eversense 365 launches. The system pairs an implanted sensor with a removable transmitter and a phone app; the sensor monitors glucose for up to twelve months.
The EON Care network has more than 100 inserters, who handled over 40% of quarterly insertion procedures. Senseonics raised its year-end target to 120.
“Recent investments in commercial infrastructure are expanding patient access, supporting our growth and improving gross margins,” Senseonics President and CEO Tim Goodnow said in the earnings release.
Its existing Sequel partnership connects Eversense 365 with the twiist automated insulin-delivery system. Senseonics also announced a Beta Bionics partnership to connect the monitor with the iLet Bionic Pancreas insulin-delivery system, and started human testing of Freedom, an investigational monitor designed to communicate with phones without an on-body component.
Senseonics plans to launch the Beta Bionics integration commercially in the fourth quarter of 2026, pending completion of integration work and applicable requirements.
Sources
- 8-K Filing — Senseonics Holdings, Inc. (SENS) — SEC EDGAR
- Exhibit sens-ex99d1.htm — Senseonics Holdings, Inc. 8-K exhibit — SEC EDGAR
- Senseonics Holdings, Inc. Reports Third Quarter 2026 — globenewswire.com